vesicare 5 mg 5 mg tabletki powlekane
astellas pharma sp. z o.o. - solifenacyny bursztynian - tabletki powlekane - 5 mg
vesicare 10 mg 10 mg tabletki powlekane
astellas pharma sp. z o.o. - solifenacyny bursztynian - tabletki powlekane - 10 mg
anturin 5 mg tabletki powlekane
us pharmacia sp. z o.o. - solifenacini succinas - tabletki powlekane - 5 mg
nifelox 5 mg tabletki powlekane
synoptis pharma sp. z o.o. - solifenacini succinas - tabletki powlekane - 5 mg
pimafucort (10 mg + 10 mg + 3500 i.u.)/g krem
leo pharma a/s - natamycinum + neomycinum + hydrocortisonum - krem - (10 mg + 10 mg + 3500 i.u.)/g
pimafucort (10 mg + 10 mg + 3500 i.u.)/g maść
leo pharma a/s - natamycinum + hydrocortisonum + neomycinum - maść - (10 mg + 10 mg + 3500 i.u.)/g
levact 2,5 mg/ml proszek do sporządzania koncentratu roztworu do infuzji
astellas pharma gmbh - bendamustini hydrochloridum - proszek do sporządzania koncentratu roztworu do infuzji - 2,5 mg/ml
nifelox 10 mg tabletki powlekane
synoptis pharma sp. z o.o. - solifenacini succinas - tabletki powlekane - 10 mg
protopic
leo pharma a/s - takrolimus - zapalenie skóry, atopowe - inne preparaty dermatologiczne - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. występuje cztery lub więcej razy w roku), które miały początkowy odpowiedzi do maksymalnie sześciu tygodni leczenia dwa razy dziennie maści takrolimus (ogniska oczyszczone, prawie wyczyszczone lub słabo wpływa).
asamax 250 250 mg tabletki dojelitowe
astellas pharma sp. z o.o. - mesalazinum - tabletki dojelitowe - 250 mg